MiMedx Planning U.S. Launch for Ambient Temperature Version of OrthoFlo

By Julie A. Vetalice

MiMedx is planning a U.S. launch for a next-generation lyophilized (freeze-dried) version of OrthoFlo, its amniotic fluid-based allograft for use in in orthopaedic and sports-medicine applications.

This anticipated version of OrthoFlo can be stored at ambient temperature and has a five-year shelf life.

Date of product launch was not specified.

Source: MiMedx Group Inc.


Product Labels: PRP/Cell-Based/Osteoinductive Materials

Tags: Product Launch